University of Alberta

Kmt Hepatech, Inc.

Medizinische Hochschule Hannover

Other

University System of Maryland

D Lorne Tyrrell

Norman M Kneteman

Michael Houghton

David Frederick Mercer

Abdolamir Landi

Michael A Joyce

James Nieman

Michael Manns

Tobias Weismueller

Appan Srinivas Kandadai

Mostofa Hena

Alexandr Belovodskiy

Tim Lankisch

Wen Fu

Jack Jhamandas

Kimberley Zimmerman

Karl Fischer

Ryoichi Kimura

Kamlesh Kumar Sahu

John Elliott

Lung-Ji Chang

Bing Bai

Abdu F Azad

Maurizia Rossana Brunetto

Ferrucio Bonino

Aldo Montano-Loza

Ana Clementin

Hendrikje Geesje Steenbergen

Sumonta Chaisomchit

John B Sacci, Jr

M Joanne Lemieux

Elena Arutyunova

The present disclosure provides compounds that are amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the amylin receptor antagonists for treating, preventing, or ameliorating Alzheimer's disease. Aspects of the present disclosure include a method of inhibiting activity of an amylin receptor by administering to a subject in need thereof a therapeutically effective amount of an amylin receptor antagonist.

Compounds for the treatment of Alzheimer's disease

The present disclosure provides compounds and methods for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection. Aspects of the present disclosure also include methods of treating a Baltimore Group IV RNA virus infection in a subject. The present disclosure also provides pharmaceutical compositions related to the same.

RNA virus inhibitor compounds and uses thereof

The present disclosure provides methods and compositions that find use in identifying presence of an advanced stage autoimmune liver disease (ALD) is a subject diagnosed as having ALD. Also provided here are methods and compositions that find use in monitoring effectiveness of treatment of an ALD patient receiving a treatment for the ALD. Also provided here are methods and compositions that find use in identifying subjects suffering from a relapse of ALD. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject having ALD.

Biomarkers in autoimmune liver disease

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.

Methods and compositions for treatment of autoimmune hepatitis

The present disclosure provides methods and compositions relating to in vitro cultures of human hepatocyte cell lines which exhibit a primary human hepatocyte phenotype. Such cell lines are susceptible to infection by a hepatotrophic virus, such as HCV or HBV, and support both viral replication and high levels of viral particle production. Such in vitro cultures find use in production and study of hepatotrophic virus, as well as methods of screening (e.g., for antiviral drugs, assessing drug metabolism), and study of primary human hepatocytes.

Methods for producing cells having a phenotype of a primary human hepatocytes and compositions

Methods of treatment of primary sclerosing cholangitis

Methods and compositions for diagnosis of inflammatory liver disease

The present invention provides non-naturally occurring polypeptides that specifically bind hepatitis B virus (HBV) DNA; and polynucleotides encoding the polypeptides. The present invention further provides methods of detecting HBV DNA; methods of detecting a covalently closed circular DNA (cccDNA) form of HBV; and methods for treating HBV infection.

Hepatitis B virus-binding polypeptides and methods of use thereof

The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.

Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection

Animal model having a chimeric human liver

The present invention features a non-human animal model of malaria, e.g.,, particularly. The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having anti-pathogenic activity against malaria.

Malarial animal model having a chimeric human liver

Growing community of inventors

Edmonton, Canada

D Lorne Tyrrell